dr. hope rugo on safety of trastuzumab biosimilar for her2 breast cancer
Published 7 years ago • 344 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
1:30
dr. hope rugo on trastuzumab biosimilar in her2-positive breast cancer
-
1:00
dr. dang on the significance of the myl-1401o biosimilar in her2-positive metastatic breast cancer
-
49:25
optimizing therapy in her2 disease with dr. hope s. rugo
-
1:43
dr. rugo discusses the equivalency of trastuzumab biosimilars
-
2:35
dr. rugo on the phase iii sophia trial in her2 breast cancer
-
1:05
dr. rugo on ongoing trials in her2 breast cancer
-
1:53
dr. rugo discusses a comparative review of trastuzumab biosimilars
-
1:55
dr. rugo on pathway blockade in breast cancer
-
1:37
dr. rugo discusses the regulatory process behind biosimilars
-
1:33
dr. hope rugo on the first-line superiority of paclitaxel for advanced breast cancer
-
0:55
dr. rugo on the future of extended adjuvant hormone therapy for breast cancer
-
3:49
novel strategies for her2 metastatic breast cancer; biosimilars
-
1:36
dr. rugo on the efficacy of bevacizumab in breast cancer
-
3:04
dr. rugo on 20-year span of breast cancer advancements
-
1:53
dr. hope rugo examines angiogenesis inhibition for advanced breast cancer
-
1:24
dr. rugo on extended adjuvant hormone therapy for breast cancer
-
1:40
dr. esteva on clinical trial design of trastuzumab biosimilar in her2 breast cancer
-
3:38
biosimilar trastuzumab
-
1:20
dr. rugo on hormone therapy for patients with breast cancer